Alkermes Plc (ALKS)vsViatris Inc (VTRS)
ALKS
Alkermes Plc
$29.37
+3.42%
HEALTHCARE · Cap: $4.73B
VTRS
Viatris Inc
$13.50
+1.05%
HEALTHCARE · Cap: $15.39B
Smart Verdict
WallStSmart Research — data-driven comparison
Viatris Inc generates 869% more annual revenue ($14.30B vs $1.48B). ALKS leads profitability with a 16.4% profit margin vs -24.6%. VTRS appears more attractively valued with a PEG of 0.14. ALKS earns a higher WallStSmart Score of 53/100 (C-).
ALKS
Buy53
out of 100
Grade: C-
VTRS
Buy50
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-259.2%
Fair Value
$9.72
Current Price
$29.37
$19.65 premium
Intrinsic value data unavailable for VTRS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Reasonable price relative to book value
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Revenue declined 10.6%
Earnings declined 67.0%
ROE of -21.1% — below average capital efficiency
Earnings declined 70.6%
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : ALKS
The strongest argument for ALKS centers on Debt/Equity, Price/Book. Profitability is solid with margins at 16.4% and operating margin at 15.1%.
Bull Case : VTRS
The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.14 suggests the stock is reasonably priced for its growth.
Bear Case : ALKS
The primary concerns for ALKS are PEG Ratio, Revenue Growth, EPS Growth.
Bear Case : VTRS
The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
ALKS profiles as a declining stock while VTRS is a turnaround play — different risk/reward profiles.
VTRS carries more volatility with a beta of 0.80 — expect wider price swings.
VTRS is growing revenue faster at 5.0% — sustainability is the question.
VTRS generates stronger free cash flow (551M), providing more financial flexibility.
Bottom Line
ALKS scores higher overall (53/100 vs 50/100), backed by strong 16.4% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alkermes Plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Alkermes plc, a biopharmaceutical company, researches, develops and markets pharmaceutical products to address the unmet medical needs of patients in various therapeutic areas in the United States, Ireland and internationally. The company is headquartered in Dublin, Ireland.
Visit Website →Viatris Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?